之江生物跌2.9% 2021年上市超募5.9亿元

Core Viewpoint - Zhijiang Biology (688317.SH) is currently experiencing a decline in stock price, closing at 25.11 yuan with a drop of 2.90%, resulting in a total market capitalization of 4.825 billion yuan, indicating the stock is in a state of breaking below its initial public offering price [1] Group 1: Company Overview - Zhijiang Biology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 18, 2021, with an issuance of 48,676,088 shares at an initial price of 43.22 yuan per share [1] - The highest stock price recorded was 93.80 yuan, reached on the sixth trading day after the IPO [1] Group 2: Fundraising and Financials - The total amount raised from the initial public offering was 2.10378 billion yuan, with a net amount of 1.94232 billion yuan, exceeding the original plan by 586.43 million yuan [1] - The company initially planned to raise 1.35589 billion yuan, which was intended for various projects including the upgrade of in vitro diagnostic reagent production lines and the establishment of a molecular diagnostic engineering research center [1] - The total issuance costs amounted to 161.4589 million yuan, with underwriting and sponsorship fees accounting for 144.9505 million yuan [1]